Lovir Ointment Indications
Lovir 30mg 4.5gm Oint is primarily indicated in conditions like Cytomegalovirus infection prophylaxis, Encephalitis, Herpes simplex, Herpes simplex (in immunocompromised patients), Herpes simplex infection of mucous membrane, Herpes simplex infection prophylaxis, Herpes simplex keratitis, Prophylaxis of herpes simplex, Severe initial genital herpes, Simplex encephalitis, Treatment of herpes simplex, Varicella and herpes zoster, Varicella zoster infections, Varicella-zoster, Varicella-zoster (chickenpox-shingles), Viral conjunctivitis, and can also be given in adjunctive therapy as an alternative drug of choice in Herpes simplex (prevention of recurrence), Prevention of recurrence of herpes simplex, Treatment of herpes simplex (immunocompromised patients).
Lovir 30mg 4.5gm Oint is contraindicated in conditions like Hypersensitivity.
The severe or irreversible adverse effects of Lovir 30mg 4.5gm Oint, which give rise to further complications include Rises in blood urea and creatinine, Encephalopathy, Seizures, Acute renal failure, Renal tubular obstruction.Lovir 30mg 4.5gm Oint produces potentially life-threatening effects which include Coma. which are responsible for the discontinuation of Lovir 30mg 4.5gm Oint therapy. The symptomatic adverse reactions produced by Lovir 30mg 4.5gm Oint are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Vomiting, Anorexia, Severe local inflammatory reactions, Tremors, Abdominal pain, Skin rashes, Confusion, Erythema, Lethargy, Itching, Hallucination, Malaise, Elevation of liver enzymes, Contact dermatitis, Agitation, Stinging on application, Crystalluria, Transient burning, Reaction at injection site, Confusion, Skin rashes.
This medication should be used with caution during pregnancy and lactation. Topical preparation (e.g cream) is not recommended for application to mucous membranes, particular care should be taken to avoid accidental introduction into the eyes.
There are no reviews yet.